Format

Send to

Choose Destination
Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2.

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.

Author information

1
a Department of Radiation Biology , The Finsen Center, Rigshospitalet , Copenhagen , Denmark.
2
b Department of Oncology , The Finsen Center, Rigshospitalet , Copenhagen , Denmark.
3
c Department of Surgical Gastroenterology , Hvidovre Hospital , Hvidovre , Denmark.
4
d Department of Pathology , Center of Diagnostic Investigation, Rigshospitalet , Copenhagen , Denmark.
5
e Department of Neurosurgery , Neuroscience Centre, Rigshospitalet , Copenhagen , Denmark.
6
f Department of Radiology , Center of Diagnostic Investigation, Rigshospitalet , Copenhagen , Denmark.
7
g Phase I Unit, The Finsen Center, Rigshospitalet , Copenhagen , Denmark.

Abstract

Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are tested for association with progression-free survival, overall survival, and response to bevacizumab and irinotecan therapy. Significant factors from univariate screening are included in multivariate analysis. Biomarkers previously advanced as predictive or prognostic in the first-line setting did not affect outcome in this patient cohort. Based on the optimized model for overall survival, comprising performance status and p53 expression, a prognostic index is established.

KEYWORDS:

Bevacizumab; Cancer biomarkers; Glioma; Prognosis and response predictions; Recurrent

PMID:
29393706
DOI:
10.1080/07357907.2018.1430818
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center